Tobramycin/dexamethasone - Alcon

Drug Profile

Tobramycin/dexamethasone - Alcon

Alternative Names: Dexamethasone/tobramycin - Alcon; TobraDex; Tobradex AF; TobraDex ST

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alcon
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 23 Sep 2010 Launched for Ocular inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top